Pumactant

Identification

Generic Name
Pumactant
DrugBank Accession Number
DB04955
Background

Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

Type
Small Molecule
Groups
Investigational
Synonyms
  • ALEC

Pharmacology

Indication

Investigated for use/treatment in asthma, lung injury, and surgical adhesions.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Pumactant is known as a lung (pulmonary) surfactant. Surfactants are wetting agents which coat the surface of the air sacs (alveoli) and reduce surface tension in the lungs. This helps to inflate and expand the air sacs during breathing and prevents their collapse. Surfactants are normally produced naturally in the lungs. A failure by the lungs to do this results in a life threatening disorder known as respiratory distress syndrome, where the lungs become stiff, uninflatable and make breathing extremely difficult. This commonly occurs in premature babies, where their under-developed lungs are incapable of producing surfactants. Pumactant is given directly into the lung through a tube (endotracheal administration), to replace the natural surfactant and therefore aids breathing in premature babies.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Not Available
CAS number
258856-56-3

References

General References
  1. Babu KS, Woodcock DA, Smith SE, Staniforth JN, Holgate ST, Conway JH: Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J. 2003 Jun;21(6):1046-9. [Article]
  2. Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, Ward Platt MP: Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet. 2000 Apr 22;355(9213):1387-92. [Article]
  3. Young PM, Thompson J, Woodcock D, Aydin M, Price R: The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy. J Aerosol Med. 2004 Summer;17(2):123-8. [Article]
PubChem Substance
347909857
Wikipedia
Pumactant

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52